Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2
Download
03
Our Dynamo® platform and approach are creating new possibilities in drug discovery
Program
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
RLY-4008
FGFR2
RLY-2608
PI3KαPAN
Breast Cancer & Solid Tumors
RLY-2608
PI3KαPAN
Vascular Malformations
Fabry Disease
αGal
NRAS
RLY-1013
ERα Degrader
RLY-2139 (paused)
CDK2
Discovery Programs (5+)
While our initial focus has been on enhancing small molecule therapeutic discovery in precision oncology, protein conformational dynamics are implicated in a wide variety of therapeutic areas. We have also leveraged the power of our Dynamo platform to extend to genetic disease as well.
Our current discovery programs are focused in targeted oncology (3) and genetic disease (2).
We also continue to evaluate potential additional therapeutic areas beyond precision oncology and genetic disease that we could enter in the future.
Publications/
Presentations
Download
Download
Download
Download
Download
Download
Download
Download
Download
Download
Download
Download
Download
Download
Download
Download
Download
Download
At Relay Therapeutics, we know that patients need new medicines now. This is the driving force behind everything we do.